Biocon, India’s largest biotech company, is focused on delivering affordable innovation by leveraging India’s cost advantage to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases.

Biocon – delivering affordable innovation

Biocon’s discovery-led R&D focuses on the entire drug development pathway, from process development, to non-clinical and clinical research. R&D’s ability to develop new solutions continues to advance Biocon’s reputation as an emerging global biopharma focusing on delivering affordable innovation. Biocon is advancing its in-house R&D programs and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through. Biocon has developed a robust novel and biosimilars pipeline, focusing on Oncology, Diabetes and auto-immune diseases, which has several molecules at different stages of the development cycle.

Biocon’s key innovations include world’s first Pichia based recombinant human Insulin, INSUGEN, which has successfully completed phase III EU clinical study. The insulin analogue Glargine, BASALOG, has completed global phase I. The monoclonal antibody BioMAb-EGFR is very promising against head and neck cancers. Biocon also launched ALZUMAb, an anti-CD6 monoclonal antibody for the treatment of chronic plaque psoriasis in 2013. BVX 20, a novel molecule for oncology, has also recently entered clinical trials. CANMAb, trastuzumab for the treatment of HER2-positive metastatic breast cancer was developed jointly by Biocon and Mylan, and entered global phase III.

Biocon, Asia’s leading biotech enterprise, is based in Bangalore (India) and leaded by Kiran Mazumdar-Shaw as Managing Director. The high quality scientific talents (a 3000-strong team of bioscientists, engineers and business managers) are engaged in continuous interaction with international leaders participating in technical programs to enable knowledge creation, positioning Biocon’s R&D as a key factor for challenging biopharmaceutical developments. Biocon’s custom research organisation, Syngene, offers modular and integrated services in small and large molecule discovery and development. Offering meticulous IPR protection, Biocon provides customised solutions to pharmaceutical, chemical, biotechnology and agrochemical industries in the areas of biology, process development, scale-up, formulation and analytical developments. Biocon’s aspiration to become soon a 1billion$ company is fuelled by partnerships and customers in more than 75 countries.

More about Biocon : www.biocon.com

Biocon – drug development – recombinant human Insulin – INSUGEN – BASALOG – BioMAb-EGFR – ALZUMAb – anti-CD6 monoclonal antibody – CANMAb – trastuzumab – Mylan – BVX 20 – Syngene

Biocon – diabetes – cancer – autoimmune disease – Pichia – Kiran Mazumdar-Shaw